Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 1796-1803, 2005. First published August 11, 2005; 10.1373/clinchem.2005.049908
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Data Supplements
Right arrow All Versions of this Article:
clinchem.2005.049908v1
51/10/1796    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (16)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Amacher, D. E.
Right arrow Articles by Townsend, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Amacher, D. E.
Right arrow Articles by Townsend, R. R.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2005;51:1796-1803.)
© 2005 American Association for Clinical Chemistry, Inc.

Proteomics and Protein Markers

Use of Proteomic Methods to Identify Serum Biomarkers Associated with Rat Liver Toxicity or Hypertrophy

David E. Amacher1,a, Rick Adler2, Athula Herath3 and R. Reid Townsend4

1 Molecular & Investigative Toxicology, World Wide Safety Sciences, Groton, CT.
2 World Wide Safety Sciences, Ann Arbor, MI.
3 Bioinformatics, Nestle Research Center, Lausanne, Switzerland.
4 Washington University School of Medicine, Department of Internal Medicine, St. Louis, MO.

aAddress correspondence to this author at: Molecular & Investigative Toxicology, World Wide Safety Sciences, Mailstop 8274-1227, Pfizer Inc., Groton, CT 06340. Fax 860-441-5499; e-mail david.e.amacher{at}pfizer.com.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Background: Our objectives were to identify serum marker proteins in rats that might serve as sensitive indicators of hepatomegaly, hepatocellular necrosis, or hepatobiliary injury and to use them to analyze data from a collaborative proteomics project.

Methods: In each of 4 studies comprising the collaborative project, rats were given 1 of 4 compounds that target the liver through different mechanisms. Sera and liver samples were collected by terminal bleeds at 1 of 3 postdose time points. Sera were depleted of major secretory proteins and then separated into protein features by 2-dimensional gel electrophoresis (2DGE). Liver specimens were also processed and subjected to 2DGE. Protein spots that significantly increased or decreased in quantity after drug treatment were recovered, digested, analyzed by mass spectroscopy, and compared with available databases for identification. Criteria for further consideration were (a) temporal expression (i.e., increase or decrease at early, fulminant, or recovery periods), (b) known biological function, (c) probable hepatic origin, and (d) any previous association with toxicity in published studies. Markers that changed significantly at the early time point were important because of their potential sensitivity for signaling minimal damage.

Results: Vitamin D–binding protein, paraoxonase, cellular retinol-binding protein, malate dehydrogenase, F-protein, and purine nucleoside phosphorylase were identified as empirically confirmed serum markers for hepatic effects in drug-treated rats.

Conclusion: Proteomics can be applied for the identification and confirmation of peripheral biomarkers for altered liver function after toxicant exposure.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Hepatic responses to chemical toxicants can be acute or chronic. Histologically they can be characterized as hepatocellular or hepatobiliary, and they can be of intrinsic or secondary origin. Tissue injury by hepatotoxicants depends on the dose and duration of exposure, the principal cell population affected, and the mechanism of action. Conventional diagnostic monitoring makes use of noninvasive serum chemistry and hematology markers that are often associated with known cellular damage or functional changes, and histopathologic examination, which requires either biopsy or necropsy specimens. We used a series of archetypal liver-targeting agents to model specific hepatic injuries or changes often encountered in safety evaluation studies and then searched for chemically induced alterations in the expression of highly specific gene products. The latter may serve as particularly sensitive indicators of various hepatic effects under experimental conditions not necessarily producing frank tissue damage or functional alteration. Thus, these gene products may function in restoration, detoxification, or protection or may be involved in cell-signaling pathways leading to the selective death of damaged cells or compensatory proliferation of surviving cells.

Two-dimensional gel electrophoresis (2DGE) 1 permits the resolution and analysis of up to several thousand proteins from complex mixtures such as liver homogenates or blood. Proteomic analysis by 2DGE can determine the steady-state condition of the proteome, including posttranslational modification, turnover/stability, subcellular compartmentalization, and possibly drug–protein binding. Analysis results are easily evaluated by comparison with conventional toxicity data. Of particular interest in preclinical and clinical safety assessment are biomarkers in the peripheral circulation that are quantitatively altered functionally or morphologically after exposure to liver toxicants. Previous rat studies have clearly established the value of tissue proteomic profiling for examples that include a hypoglycemic agent and a statin hydroxymethylglutaryl-CoA reductase inhibitor for both efficacy and toxicity and an antidiabetic candidate for drug-induced liver steatosis (1). Even more important would be applications involving proteomic profiling that include both liver and sera.

As part of a Pfizer/Oxford Glycosciences collaboration, 4 drugs differing in their mechanism for producing hepatic damage or functional change were used to induce hepatotoxicity or hepatomegaly in male CD® rats. Acetaminophen has been associated with hepatocellular necrosis, {alpha}-naphthylisocyanate (ANIT) with intrahepatic cholestasis, and phenobarbital and Wy-14, 643 with hepatomegaly via hypertrophy or cell proliferation (2)(3)(4)(5). Each study incorporated time points corresponding to early and fulminant toxicity expectations and a third time point for recovery or restoration. Conventional clinical chemistry analyses of serum and histopathologic examination of liver confirmed the expected hepatic effects for these studies. The subsequent proteomic analyses of sera from 3 time points for each of the 4 independent studies are summarized here with the identification of some protein biomarkers that correlated with actual hepatic effects.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
animal studies
For each study, male Sprague–Dawley rats [Crl:CD(SD)BR] obtained from Charles River Laboratories were distributed into 3 groups (n = 5 per group) corresponding to 3 scheduled necropsy dates. Animals of similar weight distribution were selected by a computer-based randomization procedure. In a similar manner, rats were selected and distributed into 3 concurrent vehicle control groups (n = 5 per group) for each of the 4 studies. All studies were conducted in compliance with the US Animal Welfare Act and the ILAR Guide (1996). Rats in the 4 studies received one of the following treatments: (a) a single 1000 mg/kg dose of acetaminophen by oral intubation (20 mL/kg) or, for control animals, an equivalent dose volume of 5 g/L methylcellulose (in deionized water) vehicle on all dosing days; (b) ANIT in 1 dose by oral gavage (10 mL/kg) at 100 mg/kg or, for control animals, an equivalent dose volume of corn oil vehicle on the day of dosing; (c) either 1 or 4 daily doses of phenobarbital (100 mg · kg–1 · day–1) by oral gavage (10 mL/kg) or, for control animals, an equivalent dose volume of deionized water vehicle on all dosing days; (d) either 1 or 3 daily doses of Wy-14, 643 (45 mg · kg–1 · day–1) by subcutaneous injection (0.2 mL/kg) or, for control animals, an equivalent dose volume of corn oil vehicle on all dosing days. Animals were killed and tissue samples taken at the following time points: acetaminophen, 8 h, 18 h, and 3 days; ANIT, 12 h, 2 days, and 5 days; phenobarbital, 2 h, 5 h, and 12 days; and Wy-14, 643, 2 h, 4 h, and 15 days. These discrete time points were individually selected for each compound based on published data and internal experience with these same chemicals, but included 4 categories for each drug: (a) an early time point, before manifestation of toxicity (controls); (b) concurrent with the early appearance of lesions or clinical chemistry markers; (c) late stage when hepatic injury is fully manifest or fulminant; and (d) post recovery after cessation of treatment.

proteomics procedures
Venous blood was collected at the time of necropsy. Serum was obtained by centrifugation, and 100 µL was added to 15 µL of protease inhibitor and frozen at –80 °C. At the same time, a 2-g section of the median lobe was removed to a conical tube and quick-frozen in liquid nitrogen. The frozen liver section was later pulverized for 1 min with a freezer mill, after which 10–20 mg of pulverized liver was solubilized with 10 µL of protease inhibitor and 1.5 mL of lysis solution and mixed. The sample was allowed to remain at room temperature for 10 min and then was mixed again and pelleted with an Eppendorf 5417R Centrifuge for 10 min at 13 000g at 15 °C. The resulting supernatant was frozen at –80 °C. All samples were coded to conceal their identities and then were shipped to the United Kingdom where 2-dimensional gradient gels were spotted and run by the Oxford Glycosciences staff. A detailed description of the 2DGE procedure, analysis of gel images, and methods for protein identification by mass spectrometry (MS) have been reported previously (6). Before electrophoresis, serum samples were passed through an affinity depletion column described previously for cerebrospinal fluid (7) to remove substantial proportions of albumin, transferrin, haptoglobin, {alpha}1-antitrypsin, and IgG to increase the resolution of the system. After electrophoresis, gel features were visualized by use of a nondenaturing fluorescent marker (OGT MP 17) and assigned pI and molecular weight values, and the volume (i.e., spot size and intensity) and percentage volume were calculated. In reference to a single master gel for each study and using Rosetta software, each feature was assigned a master cluster index (MCI) number denoting a unique protein within a tissue type. This procedure has been described in detail elsewhere (7). A representative liver master gel from the ANIT study is shown as Fig. 1 . A total of 12 919 MCI (liver) or 22 002 MCI (serum) were included in the master group. Each MCI within a study was subjected to a visual quality-control inspection to confirm its validity. Only MCI that were significantly increased or decreased (P <0.05) compared with a control master gel were evaluated further. Gel pieces (MCIs) were subjected to trypsinolysis, and the supernatant was extracted. A small portion (~10%) was directly assayed via matrix-assisted laser desorption/ionization (MALDI). The MALDI spectrum was used as a first quality-control tool and also to give a list of masses for the next step. The remainder of the sample was then submitted for tandem MS analysis (by liquid chromatography quadruple ion trap if the peaks were high intensity or by quadruple time of flight if the peaks were low intensity). The masses obtained from MALDI guided the operators concerning which ions to analyze further. The tandem spectra were used for protein identification by comparison of a peptide sequence tag with a sequence in a rodent public domain database. Those not identified in the former were then compared with a human database for possible matches to human homologs.



View larger version (62K):
[in this window]
[in a new window]
  		Figure 1. Representative master gel from the ANIT study.

Gels containing experimental samples were all mapped to coordinates defined by a single master gel for either serum or liver per study.

statistical analyses
For the conventional clinical pathology and liver weight data, statistical analyses were performed separately for each treatment group vs the corresponding control group as follows. For each collection period, each treated group mean was compared with the control group mean. The Dunnett multiple comparison procedure was used if a preliminary Bartlett test for variance homogeneity was not significant at the {alpha} = 0.05 level. If there was significant variance heterogeneity, the Cochran–Cox modified t-test was used for comparison between treated and control group means. Statistical significance of the comparisons was indicated at both the {alpha} = 0.05 and 0.01 levels. Tests were 2-tailed. For the proteomics data, P values were obtained by both the Wilcoxon rank-sum test (with substitution for missing values) and the Student t-test. With the Wilcoxon rank-sum test, we characterized MCIs by a significant difference between treated (a minimum of 4 of 5 animals were required for consideration) vs control at P <0.05. Results were clustered according to a double Venn diagram into early, full, and recovery categories, which are illustrated in Fig. 2 , with the overlap showing cofrequency. Because of resource limitations, only features falling into categories 1, 4, and 5 were annotated and are described here.



View larger version (22K):
[in this window]
[in a new window]
  		Figure 2. Venn diagram showing the 8 categories for liver proteins.

*, statistically significant difference at the 0.05 significance level.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
animal studies
A detailed description of the gross pathology observations and histopathology findings for each of the 4 studies is given in file 1 of the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol51/issue10/. The clinical chemistry changes for these studies are summarized in Table 1 of the online Data Supplement.


View this table:
[in this window]
[in a new window]
  		Table 1. Summary of serum proteins characterized by possible liver origin and significantly (P <0.05) altered expression after exposure of male rats to chemicals that affect the liver.

proteomics results
For each of the 12 919 or 22 002 MCIs in the master groups, a differential analysis between control and treated samples was performed at 3 time points, early, peak (full) toxicity, and recovery. In addition to the comparisons by the Wilcoxon rank-sum test and t-tests based on the null hypothesis that the treated and control samples have equal means, fold changes were calculated. These were the ratios of the mean of the treated samples to that of the control and were used to measure up- or down-regulation. On the basis of statistical significance, the MCIs were examined for possible errors in feature quantification and mismatches. Subsequently, MS-based identification of gel features was performed as described in the Materials and Methods. For the liver tissues, 180 gel images and 220 781 features were analyzed by use of 6 master groups, yielding 12 919 MCIs and 184 cut features (post–quality-control analysis), of which 124 were annotated. For the serum samples, 179 gel images and 187 377 features were analyzed by use of 6 master groups, yielding 22 002 MCIs and 243 cut features (post–quality-control analysis), of which 101 were annotated.

In the same study animals, 61% of the serum proteins that were significantly altered after drug treatment were down-regulated, whereas 84% of the altered liver proteins were up-regulated. The liver and sera profiles for each study are shown in Figs. 1Up and 2Up of the online Data Supplement. In sera, the largest proportion of proteins that were altered (33%) was affected in the early time period. The identification of those annotated proteins with likely toxicologic significance that were most affected by drug treatment are tabulated for liver and sera, respectively (see Tables 2 and 3 of the online Data Supplement). A summary analysis of 19 significantly altered serum proteins from the 4 studies can be found in Table 1Up . These were selected from a total of annotated protein features based on criteria that included (a) probable or exclusive liver origin, (b) evidence of a human homolog, and (c) evidence of a statistically significant (P <0.05) change with treatment. All 19 proteins in Table 1Up have been reported previously to be present in human sera or plasma and thus may be relevant clinically if altered by drug treatment with liver toxicants in preclinical studies.

Significant increases in alanine aminotransferase (ALT) occurred 18 h after treatment with acetaminophen, which causes hepatocellular death at high acute doses, but not at 8 or 72 h postdose. The principal treatment-related histopathologic finding was centrilobular necrosis evident in 5 of 5 rats at 18 h postdose. Thus, acute administration of acetaminophen produced progressive hepatocellular necrosis, an effect that subsided after a 54-h recovery period. The proteomic results indicated that acetaminophen treatment caused significant increases in 10 and decreases in 11 proteins, excluding the conventional clinical chemistry endpoints. At the fulminant time point, F-protein (hydroxyphenylpyruvate dioxygenase) was increased >5-fold in treated compared with control animals. Purine nucleoside phosphorylase (PNP) was also significantly increased, whereas paraoxonase was significantly decreased at this time point as well as at the early time point. These changes were not found at 54 h postdose, suggesting recovery or restoration. Serum F-protein has previously been cited as offering advantages over ALT for detection of minor degrees of acute liver dysfunction, particularly when only centrilobular damage is involved (9). Baseline and stimulated serum paraoxonase activities are decreased in chronic hepatitis and liver cirrhosis (10). In rats, PNP activity was demonstrated to increase 5 h after the administration of endotoxin (11).

ANIT is a hepatobiliary toxicant in rats. In this study, numerous conventional serum markers were significantly increased at the midpoint [ALT and aspartate aminotransferase (AST), alkaline phosphatase, 5' nucleotide, total bilirubin, and bile acids], with recovery noted for most at the later time point, as expected. In the fulminant dose group, 4 of 5 treated rats had single-cell hepatocyte necrosis, and all 5 treated rats had pericholangial inflammation. In the proteomics analysis, 5 serum proteins were increased and 8 were decreased. At the middle time point, cytosolic malate dehydrogenase (MDH) was increased >5-fold in some rats. At the final time point, serum hemopexin was increased 5-fold. For enolase (phosphopyruvate hydratase) and methionine adenosyltransferase (MAT), no decreases were noted at the mid and final time points, but at the early time point, >5-fold decreases were observed. {alpha}-Enolase is a housekeeping glycolytic enzyme that is not specific to liver but is strongly expressed in biliary epithelial cells (12), and {alpha}-enolase autoantibodies have been found in patients with primary sclerosing cholangitis (13). MAT catalyzes the formation of S-adenosylmethionine, an essential metabolite that in turn regulates hepatic functions such as proliferation, differentiation, and death (14). Hemopexin is a heme-binding plasma protein primarily expressed in the liver and is one of the acute-phase reactants (15)(16).

Treatment with phenobarbital produced significant increases in absolute and relative liver weight, particularly at the middle time point. Proteomic serum analysis indicated significant increases in 5 proteins and decreases in 6 other proteins in treated compared with control samples. Transferrin protein was decreased >5-fold at the early time point. Transferrin is the iron transport protein of vertebrate serum that is primarily, although not exclusively, synthesized in the liver (17). Transferrin mRNA concentrations are diminished by aflatoxin B-1 exposure in rats (18). Using the isolated perfused rat liver model and phenobarbitone treatment, Morton and Tavill (19) reported a marked decrease in hepatic ferritin iron concentration but no change in hemoglobin or plasma iron concentrations accompanied by the specific enhancement of transferrin synthesis in both control and iron-deficient livers. The results here appear similar. Other changes at the middle time point include a significant increase in apolipoprotein E (Apo E) and a decrease in {alpha}1-macroglobulin and Apo A-1. The Apo A-1 and Apo E genes are independently regulated (20). These results differ from the observation of Chao et al. (21), who found that phenobarbital increases the concentration of rat liver apo-A1 RNA, but this discrepancy is most likely attributable to the considerable time differences (16 h vs 5 days postdose in this study).

Treatment with Wy-14, 643, which is known to cause hepatic cell proliferation and peroxisome proliferation in rodents, produced significant increases in absolute and relative liver weights, particularly at the middle time point. In the proteomics analysis, 6 serum proteins were significantly increased and 7 were decreased. At the early time point, hemopexin was increased, whereas Apo E and complement C3 were decreased. Changes at the other time points generally involved other apolipoproteins or acute-phase reactants with no clear pattern.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Two-dimensional electrophoresis is an open separation system in which the separation of proteins takes place on hypothesis-free dimensions of the isoelectric point and the molecular weight. Proteins are often modified posttranslationally, and proteomic analysis provides a unique expression map that includes these modifications (5). Specific biological activity is created by glycosylated transcripts and other posttranscriptional modifications and shown by specific protein fragments. Two-dimensional electrophoresis is the most convenient and straightforward mechanism for identifying such forms, and no other complete separation mechanism or assay exists. Proteomic analysis of rat liver homogenates has been applied to the identification of protein changes corresponding to xenobiotically induced hepatomegaly (22) and is particularly useful for the detection of drug-induced posttranslational protein modifications after drug-associated liver injury that would not be detectable via mRNA profiling (23). Other workers have recently characterized all of the major protein components in serum from healthy CD rats and noted changes in rats treated with hypolipidemic or antiinflammatory drugs (24). The present study is unique in that the proteome from both liver and serum from CD rats was analyzed after treatment with 1 of 4 different xenobiotics.

In this study we critically evaluated the summary data produced by the Pfizer/OGS proteomics collaboration and identified peripheral proteins that might serve as sensitive, early indicators of dose-dependent liver toxicity involving hepatocellular necrosis, hepatomegaly, or hepatobiliary injury. Although a major limitation was the significant underrepresentation of rodent sequences in the public domain databases, the study yielded some potential biomarker candidates for further consideration. Of 101 protein features that met the quality-control and statistical relevance criteria, we identified 19 possible biomarkers for altered liver function after in vivo administration of 3 categories of hepatic agents. A few markers that were observed to both increase and decrease in the same study, perhaps because of identification errors, were eliminated from consideration. It should be noted that some of the serum proteins that were significantly affected by drug treatment are generally considered to be nonhepatic in origin, are not specific to liver (e.g., gelsolin), or are of questionable relevance (e.g., serum protease inhibitor). Of particular interest because of their potential sensitivity were hepatic markers that changed significantly at the early time point. These serum marker proteins were not consistently and proportionally expressed over the 3 time periods for a single treatment and were not accompanied by corresponding increases or decreases in the liver within the context of the proteins whose definitive identity has been established by MS. Proteins with functions associated with detoxification or repair and proteins whose expression had previously been reported in toxicant-dosed animals were of particular interest. Some, such as serum F-protein (4-hyroxyphenylpyruvate dioxygenase) and MDH, have been documented previously as serum indicators of toxicity but are not necessarily in common use today in preclinical or clinical drug development studies.

Except for an up-regulation of hepatic ALT protein (proteomic data) that followed an increase in serum ALT activity (clinical chemistry data) 54 h later in the acetaminophen recovery group, there was no correlation between the liver and serum protein changes for any of the 4 test groups. For example, decreases in the liver mitochondrial AST protein in the Wy-14, 643 animals at 2 days were not matched by a corresponding change in AST clinical chemistry activities or serum protein data for any of the 3 time periods. In general, treatment with these chemicals agents led to the up-regulation of liver proteins involved in detoxification or response to stress, such as catalase, glutathione peroxidase, sulfotransferases, serine proteinase inhibitor, heat shock proteins or chaperonins, and glutathione S-transferase. Serum protein changes were more likely to be characteristic of down-regulation, with some acute-phase reactants or previously identified biomarkers such as F-protein being altered in the expected manner.

In general, changes in individual protein content in treated vs control animals for these selected proteins were small (<3-fold) and not correlated with any significant changes in similar liver proteins. A few serum proteins ({alpha}-enolase, transferrin, hemopexin, MDH, and F-protein) were altered 5-fold or greater in treated vs control animals at some time points with some treatments. Further considerations, such as whether the protein was considered exclusively or predominantly of liver origin and the availability of established clinical assays, suggests that 5 proteins are of special interest as serum markers for hepatic toxicity or functional alterations in rats. These are vitamin D–binding protein, PNP, and MDH, which increased under drug treatment, and paraoxonase and cellular retinol-binding protein, which decreased under drug treatment conditions. Except for PNP, these significant changes occurred in the early treatment period, before extensive morphologic changes, which suggests the desired characteristic of early manifestation and, hence, sensitivity. Further evaluation by this laboratory of 3 of these markers has recently been reported in a study that included both male and female rats (25).

In summary, serum proteomic analysis data revealed the altered expression of early markers that may have future application in clinical chemistry analyses. These protein changes were statistically significant (P <0.05), and MS-based sequencing of peptides derived from these proteins in 4 rat serum studies has identified both protein markers previously cited as possible indicators and known proteins with potentially novel associations with hepatic effects. As markers of early and mechanism-specific drug hepatotoxicity, these proteins may be valuable for predicting toxicity and/or revealing toxic effects of novel drug candidates earlier than conventional methods.


   Acknowledgments
 
We wish to express our thanks for the support provided by the following: Thomas R. Steiger, Lisa Fasulo, William Kluwe, Michael Silber, Daniel Lettiere, Anthony Perretta, Pamela Destremps, Angelo Cacciatore, Thomas Shutsky, Timothy Ferris, the histopathology and clinical pathology staffs of Pfizer, and Jim Bruce and Gordon Holt, formerly of Oxford Glycosciences.


   Footnotes
 
1 Nonstandard abbreviations: 2DGE, 2-dimensional gel electrophoresis; ANIT, {alpha}-naphthylisocyanate; MS, mass spectrometry; MCI, master cluster index; MALDI, matrix-assisted laser desorption/ionization; ALT, alanine aminotransferase; PNP, purine nucleoside phosphorylase; AST, aspartate aminotransferase; MDH, malate dehydrogenase; MAT, methionine adenosyltransferase; and Apo, apolipoprotein.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Steiner S, Anderson NL. Pharmaceutical proteomics. Ann N Y Acad Sci 2000;919:48-51.[Abstract/Free Full Text]
  2. Buttar HS, Nera EA, Downie RH. Serum enzyme activities and hepatic triglyceride levels in acute and subacute acetaminophen-treated rats. Toxicology 1976;6:9-20.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  3. Chisholm JW, Dolphin PJ. Abnormal lipoproteins in the ANIT-treated rat: a transient and reversible animal model of intrahepatic cholestasis. J Lipid Res 1996;37:1086-1098.[Abstract]
  4. Crampton RF, Gray TJ, Grasso P, Parke DV. Long-term studies on chemically induced liver enlargement in the rat. I. Sustained induction of microsomal enzymes with absence of liver damage on feeding phenobarbitone or butylated hydroxytoluene. Toxicology 1977;7:289-306.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  5. Marsman DS, Cattley RC, Conway JG, Popp JA. Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643) in rats. Cancer Res 1988;48:6739-6744.[Abstract/Free Full Text]
  6. Page MJ, Amess B, Townsend RR, Parekh R, Herath A, Brusten L, et al. Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc Natl Acad Sci U S A 1999;96:12589-12594.[Abstract/Free Full Text]
  7. Soares HD, Williams SA, Snyder PJ, Gao F, Stiger T, Rohlff C, et al. Proteomic approaches in drug discovery and development. Int Rev Neurobiol 2004;61:97-126.[ISI][Medline] [Order article via Infotrieve]
  8. Greaves P. Histopathology of preclinical toxicology studies 1990:414 Elsevier Amsterdam. (cited in online Data Supplement)..
  9. Beckett GJ, Foster GR, Hussey AJ, Oliveira DB, Donovan JW, Prescott LF, et al. Plasma glutathione S-transferase and F protein are more sensitive than alanine aminotransferase as markers of paracetamol (acetaminophen)-induced liver damage. Clin Chem 1989;35:2186-2189.[Abstract/Free Full Text]
  10. Ferre N, Camp J, Prats E, Vilella E, Paul A, Figuera L, et al. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002;48:261-268.[Abstract/Free Full Text]
  11. Mochida S, Arai M, Ohno A, Yamanobe F, Ishikawa K, Matsui A, et al. Deranged blood coagulation equilibrium as a factor of massive liver necrosis following endotoxin administration in partially hepatectomized rats. Hepatology 1999;29:1532-1540.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  12. Fukuda Y, Miyazawa Y, Imoto M, Koyama Y, Nakano I, Nagura H, et al. In situ distribution of enolase isozymes in chronic liver disease. Am J Gastroenterol 1989;84:601-605.[ISI][Medline] [Order article via Infotrieve]
  13. Orth T, Kellner R. Diekmann O, Faust J, Meyer zum Buschenfelde KH, Mayet WJ. Identification and characterization of autoantibodies against catalase and {alpha}-enolase in patients with primary sclerosing cholangitis. Clin Exp Immunol 1998;112:507-515.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  14. Santamaria E, Avila MA, Latasa MU, Rubio A, Martin-Duce A, Lu SC, et al. Functional proteomics of nonalcoholic steatohepatitis: mitochondrial proteins as targets of S-adenosylmethionine. Proc Natl Acad Sci U S A 2003;:3065-3070.
  15. Delanghe JR, Langlois MR. Hemopexin: a review of biological aspects and the role in laboratory medicine. Clin Chim Acta 2001;312:13-23.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  16. Tolosano E, Altruda F. Hemopexin: structure, function, and regulation. DNA Cell Biol 2002;21:297-306.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  17. Zakin MM. Regulation of transferrin gene expression. FASEB J 1992;6:3253-3258.[Abstract]
  18. Harris AJ, Shaddock JG, Manjanatha MG, Lisenbey JA, Casciano DA. Identification of differentially expressed genes in aflatoxin B1-treated cultured primary rat hepatocytes and Fischer 344 rats. Carcinogenesis 1998;19:1451-1458.[Abstract/Free Full Text]
  19. Morton AG, Tavill AS. The role of iron in the regulation of hepatic transferrin synthesis. Br J Haematol 1977;36:383-394.[ISI][Medline] [Order article via Infotrieve]
  20. Panduro A, Lin-Lee YC, Chan L, Shafritz DA. Transcriptional and posttranscriptional regulation of apolipoprotein E, A-I, and A-II gene expression in normal rat liver and during several pathophysiologic states. Biochemistry 1990;29:8430-8435.[CrossRef][Medline] [Order article via Infotrieve]
  21. Chao YS, Pickett CB, Yamin TT, Guo LS, Alberts AW, Kroon PA. Phenobarbital induces rat liver apolipoprotein A-I mRNA. Mol Pharmacol 1985;27:394-398.[Abstract]
  22. Newsholme SJ, Maleeff BF, Steiner S, Anderson NL, Schwartz LW. Two-dimensional electrophoresis of liver proteins: characterization of a drug-induced hepatomegaly in rats. Electrophoresis 2000;21:2122-2128.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  23. Steiner S, Witzmann FA. Proteomics: applications and opportunities in preclinical drug development. Electrophoresis 2000;21:2099-2104.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  24. Gianazza E, Eberini I, Villa P, Fratelli M, Pinna C, Wait R, et al. Monitoring the effects of drug treatment in rat models of disease by serum protein analysis. J Chromatogr B 2002;771:107-130.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  25. Schomaker SJ, Amacher DE, Pruimboom-Brees I, Mirsky M. Evaluation of three serum biomarkers of hepatotoxicity: malate dehydrogenase, paraoxonase, and purine nucleoside phosphorylase [Abstract]. Toxicol Sci 2004;78(Suppl S-1):859.
  26. Haddad JG. Plasma vitamin D-binding protein (Gc-globulin): multiple tasks. J Steroid Biochem Mol Biol 1995;53:579-582.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  27. Walmod PS, Skladchikova G, Kawa A, Berezin V, Bock E. Antiepileptic teratogen valproic acid (VPA) modulates organisation and dynamics of the actin cytoskeleton. Cell Motil Cytoskeleton 1999;42:241-255.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  28. Rostom AA, Sunde M, Richardson SJ, Schreiber G, Jarvis S, Bateman R, et al. Dissection of multi-protein complexes using mass spectrometry: subunit interactions in transthyretin and retinol-binding protein complexes. Proteins Suppl 1998;2:3-11.
  29. Calamita A, Dichi I, Papini-Berto SJ, Dichi JB, Angeleli AY, Vannucchi H, et al. Plasma levels of transthyretin and retinol-binding protein in Child-A cirrhotic patients in relation to protein-calorie status and plasma amino acids, zinc, vitamin A and plasma thyroid hormones. Arq Gastroenterol 1997;34:139-147.[Medline] [Order article via Infotrieve]
  30. Walker CH. Biochemical biomarkers of ecotoxicity—some recent developments. Sci. Total Environ 1995;171:189-195.[CrossRef]
  31. Hui CK, Yuen MF, Ng IO, Tsang KW, Fong GC, Lai CL. Low molecular weight heparin-induced liver toxicity. J Clin Pharmacol 2001;41:691-694.[Abstract]
  32. Fouad FM, Mamer OA, Shahidi F. Acute-phase response in rat to carbon tetrachloride-azathioprine induced cirrhosis and partial hepatectomy of cirrhotic liver. J Toxicol Environ Health 1996;47:601-615.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  33. Stauber W, Fritz V, Esnard F, Gauthier F. Immunofluorescent localization of four serum proteinase inhibitors in normal rat liver. Histochem J 1983;15:161-166.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  34. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998;394:284-287.[CrossRef][Medline] [Order article via Infotrieve]
  35. Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abuasha B, et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 1998;139:341-349.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  36. Young WO, Goldschmidt-Clermont PJ, Emerson DL, Lee WM, Jollow DJ, Galbraith RM. Correlation between extent of liver damage in fulminant hepatic necrosis and complexing of circulating group-specific component (vitamin D-binding protein). J Lab Clin Med 1987;110:83-90.[ISI][Medline] [Order article via Infotrieve]
  37. Lee WM, Emerson DL, Young WO, Goldschmidt-Clermont PJ, Jollow DJ, Galbraith RM. Diminished serum Gc (vitamin D-binding protein) levels and increased Gc:G-actin complexes in a hamster model of fulminant hepatic necrosis. Hepatology 1987;7:825-830.[ISI][Medline] [Order article via Infotrieve]
  38. Schiodt FV, Bondesen S, Tygstrup N. [Gc-globulin in paracetamol poisoning]. Ugeskr Laeger 1996;158:6609-6612.[Medline] [Order article via Infotrieve]
  39. Hida K, Wada J, Zhang H, Hiragushi K, Tsuchiyama Y, Shikata K, et al. Identification of genes specifically expressed in the accumulated visceral adipose tissue of OLETF rats. J Lipid Res 2000;4:1615-1622.
  40. Ohkubo K, Ogata S, Misumi Y, Takami N, Ikehara Y. Molecular cloning and characterization of rat contrapsin-like protease inhibitor and related proteins. J Biochem 1991;109:243-250.[Abstract/Free Full Text]
  41. Fukushima N, Yamamoto K, Ozaki I, Sakai T. [Apolipoprotein A-I, E, C-III and LDL-receptor mRNA expression in liver diseases]. Nippon Rinsho 1993;51:407-413.
  42. Floren CH. Apolipoprotein E in hepatocellular liver disease. Scand J Clin Lab Invest 1988;48:199-203.[ISI][Medline] [Order article via Infotrieve]
  43. Averna M, Paravizzini G, Marino G, Lanteri E, Cavera G, Barbagallo CM, et al. Liver is not the unique site of synthesis of ß2-glycoprotein I (apolipoprotein H): evidence for an intestinal localization. Int J Clin Lab Res 1997;27:207-212.[ISI][Medline] [Order article via Infotrieve]
  44. Huang ZZ, Mato JM, Kanel G, Lu SC. Differential effect of thioacetamide on hepatic methionine adenosyltransferase expression in the rat. Hepatology 1999;29:1471-1478.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  45. Hiemke C, Ghraf R. Regional distribution of methionine adenosyltransferase in rat brain as measured by a rapid radiochemical method. J Neurochem 1981;37:613-618.[ISI][Medline] [Order article via Infotrieve]
  46. Sposito AC, Vinagre CG, Pandullo FL, Mies S, Raia S, Ramires JA. Apolipoprotein and lipid abnormalities in chronic liver failure. Braz J Med Biol Res 1997;30:1287-1290.[ISI][Medline] [Order article via Infotrieve]
  47. Clifford JI, Rees KR. The action of aflatoxin B1 on the rat liver. Biochem J 1967;102:65-75.[ISI][Medline] [Order article via Infotrieve]
  48. Korsrud GO, Grice HG, Goodman TK, Knipfel JE, McLaughlan JM. Sensitivity of several serum enzymes for the detection of thioacetamide-, dimethylnitrosamine- and diethanolamine-induced liver damage in rats. Toxicol Appl Pharmacol 1973;26:299-313.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  49. Mehdi H, Nunn M, Steel DM, Whitehead AS, Perez M, Walker L, et al. Nucleotide sequence and expression of the human gene encoding apolipoprotein H (ß2-glycoprotein I). Gene 1991;108:293-298.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  50. Callaghan N, Majeed T, O’Connell A, Oliveira DB. A comparative study of serum F protein and other liver function tests as an index of hepatocellular damage in epileptic patients. Acta Neurol Scand 1994;89:237-241.[ISI][Medline] [Order article via Infotrieve]
  51. Iruela-Arispe ML, Liska DJ, Sage EH, Bornstein P. Differential expression of thrombospondin 1, 2, and 3 during murine development. Dev Dyn 1993;197:40-56.[ISI][Medline] [Order article via Infotrieve]
  52. El-Youssef M, Mu Y, Huang L, Stellmach V, Crawford SE. Increased expression of transforming growth factor-ß1 and thrombospondin-1 in congenital hepatic fibrosis: possible role of the hepatic stellate cell. J Pediatr Gastroenterol Nutr 1999;28:386-392.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  53. Horn KD, Wax P, Schneider SM, Martin TG, Nine JS, Moraca MA, et al. Biomarkers of liver regeneration allow early prediction of hepatic recovery after acute necrosis. A J Clin Pathol 1999;112:351-357.
  54. Isozaki M, Masubuchi Y, Horie T. Retinol binding protein in plasma to evaluate the hepatotoxicity of rats treated with CCl4. Res Commun Mol Pathol Pharmacol 2001;110:303-310.[Medline] [Order article via Infotrieve]
  55. Isozaki M, Masubuchi Y, Horie T. Evaluation of drug-induced hepatotoxicity by plasma retinol binding protein. In Vivo 2002;16:61-65.[ISI][Medline] [Order article via Infotrieve]



The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
B. Gangadharan, R. Antrobus, R. A. Dwek, and N. Zitzmann
Novel Serum Biomarker Candidates for Liver Fibrosis in Hepatitis C Patients
Clin. Chem., October 1, 2007; 53(10): 1792 - 1799.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
B. A. Merrick, M. E. Bruno, J. H. Madenspacher, B. A. Wetmore, J. Foley, R. Pieper, M. Zhao, A. J. Makusky, A. M. McGrath, J. X. Zhou, et al.
Alterations in the Rat Serum Proteome during Liver Injury from Acetaminophen Exposure
J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 792 - 802.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Data Supplements
Right arrow All Versions of this Article:
clinchem.2005.049908v1
51/10/1796    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (16)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Amacher, D. E.
Right arrow Articles by Townsend, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Amacher, D. E.
Right arrow Articles by Townsend, R. R.
Related Collections
Right arrow Proteomics and Protein Markers

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS